HKD 0.47
(-7.0%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 147.38 Million HKD | 72.87% |
2022 | 85.25 Million HKD | 1113.26% |
2021 | 5.45 Million HKD | 114.3% |
2020 | -49.04 Million HKD | -155.59% |
2019 | 88.38 Million HKD | -35.15% |
2018 | 136.29 Million HKD | 62.79% |
2017 | 83.72 Million HKD | 50.83% |
2016 | 55.51 Million HKD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | 34.27 Million HKD | 0.0% |
2023 Q4 | 63.82 Million HKD | 0.0% |
2023 Q2 | 83.56 Million HKD | 0.0% |
2023 FY | - HKD | 72.87% |
2022 Q4 | 36.55 Million HKD | 0.0% |
2022 FY | - HKD | 1113.26% |
2022 Q2 | 48.69 Million HKD | 0.0% |
2021 FY | - HKD | 114.3% |
2021 Q2 | -8.39 Million HKD | 0.0% |
2021 Q4 | 15.42 Million HKD | 0.0% |
2020 Q2 | -25.34 Million HKD | 0.0% |
2020 Q4 | -12.38 Million HKD | 0.0% |
2020 FY | - HKD | -155.59% |
2019 Q4 | 22.32 Million HKD | 0.0% |
2019 Q2 | 68.83 Million HKD | 0.0% |
2019 FY | - HKD | -35.15% |
2018 Q4 | 21.54 Million HKD | 0.0% |
2018 FY | - HKD | 62.79% |
2018 Q2 | 35.67 Million HKD | 0.0% |
2018 Q1 | 35.67 Million HKD | 0.0% |
2017 Q1 | 20.66 Million HKD | 0.0% |
2017 Q2 | 20.66 Million HKD | 0.0% |
2017 Q4 | 35.67 Million HKD | 0.0% |
2017 FY | - HKD | 50.83% |
2016 FY | - HKD | 0.0% |
2016 Q4 | 20.66 Million HKD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
China Healthwise Holdings Limited | -117.45 Million HKD | 225.486% |
Beijing Tong Ren Tang Chinese Medicine Company Limited | 779.54 Million HKD | 81.093% |